Table 2.
Clinical trials investigating immune cell therapies in mCRC.
| Cell Therapy | Intervention/Target | Stage | Reference |
|---|---|---|---|
| TILs | Lymphodepletion + autologous TIL + IL-2 | Phase II | NCT03610490 |
| Lymphodepletion + autologous TIL + IL-2 | Phase II | NCT01174121 | |
| Lymphodepletion + autologous TIL + IL-2 | Phase II | NCT03935893 | |
| NK cells | Allogenic NK + cetuximab | Phase I | [158] |
| Adoptive transfer NK + trastuzumab/cetuximab-based chemotherapy | Phase I | [159] | |
| CAR-T cells | Anti-EGFR-IL12 CAR-T Cells | Phase I/II | NCT03542799 |
| Anti-EGFR CAR-T cells | Phase I/II | NCT03152435 | |
| Anti-MUC1 CAR-T cells | Phase I/II | NCT02617134 | |
| Anti-EpCAM CAR-T cells | Phase I/II | NCT03013712 | |
| Anti-CEA CAR-T cells | Phase I | [160] | |
| Anti-CEA CAR-T cells | Phase I | NCT02850536 | |
| Anti-CEA CAR-T cells | Phase I | NCT02349724 | |
| Anti-EGFR CAR-T cells | Phase I/II | NCT01869166 | |
| Anti-NKG2D CAR-T cells | Phase I | NCT03370198 | |
| Anti-NKG2DL CAR-(γδ) T cells | Phase I | NCT04107142 | |
| Anti-DR5 CAR-T cells | Phase I/II | NCT03638206 | |
| CAR-NK cells | Anti-MUC1 CAR-NK cells | Phase I/II | NCT02839954 |